Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 359 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer June 24, 2020 FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular... July 31, 2024 New on NCI Websites for July 2019 July 2, 2019 Curbing Production of Immune Checkpoint Protein Slows Liver Cancer in Mice February 6, 2019 Load more HOT NEWS FDA Approves Nirogacestat for Desmoid Tumours FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... ctDNA May Guide Who Needs Chemo After Colorectal Cancer Surgery Screening for Many Cancers with One Test: Uncertainty Abounds
